Congenital Heart Disease (CHD) Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The Congenital Heart Disease (CHD) market size was estimated at USD 4.47 billion in 2023 and is projected to reach USD 8.11 billion in 2030 at a CAGR of 8.87% during the forecast period 2023-2030.

Congenital Heart Disease (CHD) is a term used to describe a range of structural defects in the heart that are present at birth. These defects can involve the walls, valves, arteries, or veins of the heart, causing problems with blood flow and affecting the heart’s ability to pump blood effectively. Some congenital heart defects are mild and may not require treatment, while others can be more severe and require medical interventions such as surgery or medication. The exact cause of most congenital heart defects is not known, but a combination of genetic and environmental factors is thought to play a role.

The growth of the global Congenital Heart Disease (CHD) market is mainly driven by rising prevalence of congenital heart disease globally. Moreover, increased awareness, improved diagnostic techniques, increased awareness and better access to healthcare are expected to drive the market further. In addition, the growing emphasis on paediatric cardiology and specialized care for children are expected to drive the market further during the forecast period.

On the other hand, the high cost of treatment, limited healthcare infrastructure, and a complex regulatory environment might hamper the growth of the market during the forecast period.

The COVID-19 pandemic has had a significant impact on the growth if the Congenital Heart Disease (CHD) Market. The pandemic led to a decrease in the number of elective CHD surgeries, as hospitals prioritized the treatment of COVID-19 patients. Moreover, there was a delay in the diagnosis and treatment of CHD, as patients have been reluctant to seek medical care due to hear of contracting COVID-19. In addition, the pandemic led to an increase in the risk of complications for patients with CHD who do not contract COVID-19.

Delvens Industry Expert's Standpoint

The Congenital Heart Disease (CHD) market is expected to grow during the forecast period. This growth can be attributed to several factors. Firstly, the prevalence of CHD is estimated to be between 8 to 12 per 1000 live births. This means that about 1 in 100 new borns will have some form of CHD. Moreover, the survival rates for children with CHD have improved significantly in recent years. This is due to advances in medical technology, such as minimally invasive surgery and heart transplantation. In addition, there is a growing awareness of CHD among the general public and healthcare professionals. This is leading to earlier diagnosis and treatment of CHD, which is improving outcomes for patients.

Market Portfolio

Key Findings

• Based on type, the market is segmented into heart valve defects, heart wall defects, blood vessel defects, others. The heart wall defects dominated the market in this segment. This is due to the increase in the cases of Ventricular septal defect (VSD) or hole in the heart worldwide.
   
• Based on diagnosis, the market is bifurcated into electrocardiogram, chest x-ray, echocardiogram, transoesophageal echocardiogram, pulse oximetry, exercise stress test, cardiac CT scan or MRI, cardiac catheterization, others. Electrocardiogram dominated the market in this segment. This is because Electrocardiogram is the most common diagnostic tool to diagnose heart defects.
   
• Based on treatment, the market is segmented into medications, surgery, watchful waiting, others. Surgery dominated the market in this segment as it is the most common treatment for CHD. Surgical treatment can be performed open-heart surgery or minimally invasive surgery.
   
• Based on route of administration, the market is segmented into oral, parenteral, others. Oral route of administration dominated the market in this segment. Oral is the most common route of administration for medications. Medications taken by the mouth are absorbed into the bloodstream through the digestive system.
   
• Based on end users, the market is segmented into hospitals, specialty clinics, others. Based on end users, the market is dominated by hospitals. This is because diagnosis and treatment of CHD is most prevalent in hospitals.
   
• Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, others. Hospital pharmacies dominated the market in this segment. This can be attributed to the fact that treatment for CHD are more prevalent in hospitals.
   
• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period due to the high prevalence of congenital heart disease and technological advancements in early diagnosis of the disease.

Regional Analysis

North America to Dominate the Market

• North America is estimated to account for the largest market share during the forecast period. This is due to the high prevalence of congenital heart disease and technological advancements in early diagnosis of the disease.
   
• Moreover, the strong presence of the key players in the region is expected to drive the market during the forecast period.

Competitive Landscape

• Abbott Laboratories
• AstraZeneca Plc
• Becton Dickson & Co.
• Bio-Rad Laboratories
• Boston Scientific Corp.
• Laboratory Corporation of America Holdings (LabCorp)
• F. Hoffmann-La Roche Ltd.
• Glaxosmithkline Plc
• Janssen Pharmaceuticals, Inc.
• Medtronic
• Viatris Inc.
• Novartis Ag
• Pfizer, Inc.
• Randox Laboratories Ltd.
• Response Biomedical Corporation
• Sanofi S.A.
• Siemens Healthineers
• Thermo Fisher Scientific Inc.
• Vericel Corporation

Recent Developments

• In June 2023, Pfizer relaunched Eliquis, an anticoagulant used to prevent the gradual increase in the prevalence of stroke due to heart condition called atrial fibrillation which is a major concern being a common cause of death among adults.
   
• In July 2023, Novartis announced that the US Food and Drug Administration (FDA) approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
   
• Gain authentic and granular data access for the Congenital Heart Disease (CHD) Market to understand the trends and the factors involved in changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope